R&D boom pushes clinical trial supplies market to $8.95b
It is forecast to reach $8.95b.
The clinical trial supplies market is projected to reach $8.95b by 2031, driven by pharmaceutical and biotechnology research and development (R&D) spending.
According to MarketsandMarkets, the rising number of clinical trials and wider use of decentralised and adaptive study designs are also driving market growth.
The services segment is sub-segmented into logistics and distribution services, storage and retention services, packaging, labelling, and blinding services, manufacturing services, and comparator sourcing services.
According to the report, the logistics and distribution services segment dominated the market due to the shift toward decentralised and direct-to-patient trials, which require flexible distribution models that enable home-based delivery with real-time monitoring.
By end users, pharmaceutical and biotechnology companies dominated the market in 2025 and are expected to grow at the highest compound annual growth rate (CAGR) during the forecast period.
The segment's dominance is attributed to the rise of biologics, cell and gene therapies, and personalised medicine.
Regionally, Asia Pacific is anticipated to grow at a significant CAGR during the forecast period.
However, North America dominated the clinical trial supplies market due to its strong pharmaceutical and biotechnology industry, high R&D investments, and well-established clinical trial infrastructure.